In AML cells treated with fludarabine (FA), toll-like receptor 4 (TLR 4) or TNF-α-mediated activation of the NF-kB signaling pathway can inhibit TXNIP expression, thereby reducing FA-induced cytotoxicity and increasing cell viability (121). The gene discussed is TXNIP; the disease is acute myeloid leukemia.